← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
Autologous umbilical cord blood for pediatric acquired hearing loss
Also known as: Autologous Human Umbilical Cord Blood, Autologous Human Umbilical Cord Blood Mononuclear Fraction Cells, JB IND14312, NCT01343394
Investigator-led study
Sponsor / Institution
Investigator-led study
Program Type
Therapeutic
Modality
Cell Therapy
Stage
Phase 1
Status
Discontinued
Target Gene
—
Route / Mode
Intravenous infusion
Confidence
80%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-09
Geography
United States
Population
pediatric, infant, acquired-hearing-loss, cell-therapy
Trial IDs
1
Mechanism
Autologous human umbilical cord blood mononuclear fraction infusion evaluated for safety in children with acquired sensorineural hearing loss.
Indications
Notes
Corrected from an industry/company-owned record. ClinicalTrials.gov lists Aryn Knight as sponsor-investigator and Cord Blood Registry as an industry collaborator. The study was withdrawn with zero enrolled participants.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...
IDs: NCT01343394, JB IND14312
Key Events
Clinical Trials (1)
Data Checks
investigator-led-studyindustry-collaborator-not-primary-sponsorwithdrawn-zero-enrolled
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2